Ways to reduce the side effects of TB drugs have been found.

Vadodara: MS University researchers have discovered a new compound that reduces side effects common to the kidney and liver, leading to the potential of a new anti-TB drug.

College of Pharmacy researchers identified at least 200,000 compounds that inhibit enzymes responsible for drug interactions in other parts of the body to identify these new anti-TB drugs.    

The researchers received a patent from the Government of India and their scientific paper was published in the prestigious British Journal of Biomolecular Structure and Dynamics.

“Using advanced molecular modeling techniques, we screened these compounds as improved drug models and further drug candidates for this new anti-TB drug.”

The patent was granted for the discovery of a potent lung cancer drug.

Currently, tuberculosis is treated with a combination of antibiotics to destroy the germs..”In most cases, the standard drugs are isoniazid, rifampicin, ethambutol, and pyrazinamide. If the bacteria are resistant to these drugs, there are other options such as fluoroquinolones, aminoglycosides, bedaquiline, and delamanid.”

He added: “However, currently used drugs can cause hepatotoxicity (drugs damage the liver), nephrotoxicity (a process that occurs when drugs, chemicals or toxins damage the kidneys and cause chronic kidney disease) and other side effects.”  for the body.” However, a team of researchers at Michigan State University has taken a new approach to studying tuberculosis.

“However, currently used drugs can cause hepatotoxicity (drug-induced liver damage) and nephrotoxicity (the process that occurs when drugs, chemicals, or toxins damage the kidneys, potentially leading to chronic kidney disease),” Moromer said in the article.

However, a team of researchers at Michigan State University has taken a new approach to TB research.

“Our goal is to discover that this enzyme, found only in mycobacteria, can disrupt the structure of the bacterial cell wall and ultimately kill the bacteria,” he said.

“Since DprE1 exists only in bacteria and not in humans, the side effects on humans, especially the kidneys and liver, will be reduced,” he said.

The newly discovered molecule, the first of its kind, is a DprE1 inhibitor containing a pyrazolopyrimidine with activity against lung cancer, the researchers say.

Reference

Author: MedBlog18 Blog Team

Views: 31